Related Experiment Videos
Psychosis in Parkinson's disease
Dylan P Wint1, Michael S Okun, Hubert H Fernandez
1Department of Psychiatry, McKnight Brain Institute/University of Florida, Gainesville 32610, USA.
Journal of Geriatric Psychiatry and Neurology
|August 18, 2004
Summary
Psychosis in Parkinson's disease (PD) is common, especially in later stages. Treatment involves adjusting Parkinson's disease medications, considering atypical antipsychotics, or exploring acetylcholinesterase inhibitors.
Area of Science:
- Neurology
- Psychiatry
Background:
- Psychosis is a frequent and challenging complication in Parkinson's disease (PD).
- It disproportionately affects patients with advanced PD undergoing chronic anti-PD medication treatment.
- The precise biological mechanisms underlying PD-related psychosis are not fully understood.
Purpose of the Study:
- To review the current understanding of Parkinson's disease-related psychosis.
- To cover its epidemiology, risk factors, pathophysiology, and treatment strategies.
Main Methods:
- Literature review of existing research on PD-related psychosis.
- Analysis of neurochemical, sleep, and visual processing factors implicated in pathogenesis.
- Evaluation of current and emerging treatment guidelines.
Main Results:
- Psychosis in PD necessitates ruling out delirium and adjusting anti-PD medications.
- Atypical antipsychotics are the primary pharmacological choice after medication adjustment.
- Acetylcholinesterase inhibitors represent a potential emerging treatment option.
Conclusions:
- Management of PD-related psychosis requires a stepwise approach, starting with medication optimization.
- Further research into pathophysiology is needed to refine treatment strategies.
- Acetylcholinesterase inhibitors show promise as an alternative therapeutic avenue.